What is HC Wainwright’s Forecast for OLMA FY2024 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Equities research analysts at HC Wainwright decreased their FY2024 earnings per share estimates for shares of Olema Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($2.34) per share for the year, down from their prior estimate of ($2.27). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.32) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2024 earnings at ($0.64) EPS, FY2025 earnings at ($2.82) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($2.83) EPS and FY2028 earnings at ($2.43) EPS.

A number of other equities analysts have also recently weighed in on OLMA. JPMorgan Chase & Co. lowered their price target on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $27.00.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock opened at $9.17 on Friday. The business’s fifty day moving average price is $12.00 and its 200 day moving average price is $11.97. The firm has a market capitalization of $525.42 million, a PE ratio of -4.19 and a beta of 2.02. Olema Pharmaceuticals has a 1-year low of $8.51 and a 1-year high of $17.10.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC grew its stake in Olema Pharmaceuticals by 74.5% in the 1st quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company’s stock valued at $13,817,000 after acquiring an additional 521,562 shares during the last quarter. Entropy Technologies LP acquired a new stake in shares of Olema Pharmaceuticals in the first quarter valued at approximately $161,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Olema Pharmaceuticals during the 1st quarter worth approximately $176,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Olema Pharmaceuticals during the 2nd quarter worth approximately $945,000. Finally, Point72 Asset Management L.P. purchased a new stake in Olema Pharmaceuticals in the 2nd quarter valued at approximately $34,753,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.